Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

Annals of the Rheumatic Diseases

Volumn 72, Issue 1, 2013, Pages 43-50

  Dougados, Maxime ^a   Kissel, Karsten ^b   Sheeran, Tom ^c   Tak, Paul P ^d   Conaghan, Philip G ^e   Mola, Emilio Martín ^f   Schett, Georg ^g   Amital, Howard ^h   Navarro Sarabia, Federico ⁱ   Hou, Antony ^j   Bernasconi, Corrado ^b   Huizinga, T W J ^k  

^a Cochin Hospital ^*  (France)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c Cannock Rheumatology Centre   (United Kingdom)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^g UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^h SHEBA MEDICAL CENTER   (Israel)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^j Inland Rheumatology Clinical Trials   (United States)

^k LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PLACEBO; TOCILIZUMAB;

ABSCESS; ACUTE KIDNEY FAILURE; ADD ON THERAPY; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ACTIVITY SCORE BASED ON 28 JOINTS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; GENANT MODIFIED SHARP SCORE; HEART INFARCTION; HUMAN; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SCROTUM ABSCESS; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SKIN NECROSIS; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; METHOTREXATE; MIDDLE AGED;

EID: 84871093047     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-201282     Document Type: Article

References (25)

1. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
2. Bykerk V. Unmet needs in rheumatoid arthritis. J Rheumatol Suppl 2009;82:42-6.
3. Genant HK, Jiang Y, Peterfy C, et al. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 1998;41:1583-90. (Pubitemid 28459916)
4. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
5. Listing J, Strangfeld A, Rau R, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low - results from RABBIT, the German biologics register. Arthritis Res Ther 2006;8:R66.
6. Soliman MM, Ashcroft DM, Watson KD, et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:583-9.
7. Feely MG, O'Dell JR. Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis. Curr Opin Rheumatol 2010;22:316-20.
8. Sebba A. Tocilizumab: the first interleukin-6-receptor inhibitor. Am J Health Syst Pharm 2008;65:1413-18.
9. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97. (Pubitemid 351392039)
10. Watanabe C, Sumioka M, Hiramoto T, et al. Magnifying colonoscopy used to predict disease relapse in patients with quiescent ulcerative colitis. Inflamm Bowel Dis 2009;15:1663-9.
11. Aletaha D, Landewe R, Karonitsch T, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis 2008;67:1360-4.
12. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
13. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29. (Pubitemid 44497760)
14. Bruynesteyn K, Boers M, Kostense P, et al. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis 2005;64:179-82. (Pubitemid 40193607)
15. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13.
16. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96.
17. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37. (Pubitemid 43122183)
18. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11. (Pubitemid 38608061)
19. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
20. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45. (Pubitemid 36091645)
21. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009;68:1100-4.
22. Aletaha D, Stamm T, Kapral T, et al. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 2003;62:944-51. (Pubitemid 37159492)
23. Mainman H, McClaren E, Heycock C, et al. When should we use parenteral methotrexate? Clin Rheumatol 2010;29:1093-8.
24. Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086-93.
25. Pavy S, Constantin A, Pham T, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006;73:388-95. (Pubitemid 44056248)